Novel CXCL8 antagonists
    11.
    发明申请
    Novel CXCL8 antagonists 审中-公开
    新型CXCL8拮抗剂

    公开(公告)号:US20090022657A1

    公开(公告)日:2009-01-22

    申请号:US10573726

    申请日:2004-10-22

    CPC分类号: C07K14/5421 A61K38/00

    摘要: Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.

    摘要翻译: 趋化因子CXCL8(也称为白细胞介素-8)的新型拮抗剂可以通过产生具有位于C-末端区域的碱性氨基酸的非保守取代的特异性组合的突变体来获得。 根据本发明制备的化合物可用于在体内阻断CXCL8活性,从而提供用于治疗或预防CXCL8相关疾病的治疗组合物。

    Cxc-Chemokine Antagonists
    13.
    发明申请
    Cxc-Chemokine Antagonists 失效
    Cxc趋化因子拮抗剂

    公开(公告)号:US20080227711A1

    公开(公告)日:2008-09-18

    申请号:US12067221

    申请日:2006-10-30

    CPC分类号: C07K14/43527 A61K38/00

    摘要: A novel CXC-chemokine binding protein is cloned from the salivary glands of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.

    摘要翻译: 一种新型的CXC-趋化因子结合蛋白是从唾液分枝杆菌的唾液腺克隆出来的。 根据本发明制备的化合物可用作抗炎和免疫调节化合物以及用于治疗或预防CXC-趋化因子相关疾病。

    Cc-chemokine mutants against liver diseases
    17.
    发明申请
    Cc-chemokine mutants against liver diseases 失效
    Cc趋化因子突变体针对肝脏疾病

    公开(公告)号:US20060228327A1

    公开(公告)日:2006-10-12

    申请号:US10540234

    申请日:2003-12-22

    IPC分类号: A61K38/19 C07K14/52

    CPC分类号: A61K38/195

    摘要: CC-Chemokine mutants having reduced Glycosaminoglycans (GAG)-binding properties are effective against liver fibrotic inflammatory and/or autoimmune diseases. Particularly preferred are the mutants of CCL5/RANTES having reduced GAG-binding properties.

    摘要翻译: 具有降低的糖胺聚糖(GAG)结合性质的CC-趋化因子突变体对肝纤维化炎症和/或自身免疫疾病有效。 特别优选的具有降低的GAG结合性质的CCL5 / RANTES的突变体。

    Chemokine receptor antagonist and cyclosporin in combined therapy
    18.
    发明授权
    Chemokine receptor antagonist and cyclosporin in combined therapy 失效
    趋化因子受体拮抗剂和环孢菌素联合治疗

    公开(公告)号:US06902728B1

    公开(公告)日:2005-06-07

    申请号:US09787335

    申请日:1999-09-16

    CPC分类号: C07K14/521 Y10S514/885

    摘要: The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.

    摘要翻译: 本文公开了将趋化因子受体拮抗剂与环孢菌素一起用于产生用于治疗或预防移植器官,组织或细胞排斥的药物组合物。 用于同时,分离或顺序使用其用于上述指定治疗的活性成分的所述药物组合物也被公开和要求保护。 特别地,实验上显示使用Met-RANTES与环孢菌素A一起制备用于治疗肾同种异体移植排斥的药物组合物。